Leber Congenital AmaurosisSymptoms, Doctors, Treatments, Advances & More
Leber Congenital Amaurosis Overview
Learn About Leber Congenital Amaurosis
- Leber congenital amaurosis
- Leber congenital amaurosis 1
- Amaurosis congenita of Leber
- Congenital absence of the rods and cones
- Congenital retinal blindness
- LCA
- Leber's amaurosis
- Leber's congenital tapetoretinal degeneration
- Leber's congenital tapetoretinal dysplasia
- Amaurosis congenita of Leber, type 1
- CRB
- LCA1
- Leber congenital amaurosis type 1
- Retinal blindness, congenital
Allen Ho is an Ophthalmologist practicing medicine in Philadelphia, Pennsylvania. Dr. Ho is rated as an Elite provider by MediFind in the treatment of Leber Congenital Amaurosis. He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Retinal Vein Occlusion, Vitrectomy, and Cataract Removal. Dr. Ho is board certified in Ophthalmology. Dr. Ho is currently accepting new patients.
Scheie Eye Institute Perelman
Tomas Aleman is an Ophthalmologist practicing medicine in Philadelphia, Pennsylvania. Dr. Aleman is rated as an Elite provider by MediFind in the treatment of Leber Congenital Amaurosis. He is also highly rated in 28 other conditions, according to our data. His clinical expertise encompasses Choroideremia, Leber Congenital Amaurosis, Retinopathy Pigmentary Mental Retardation, Cone-Rod Dystrophy, and Vitrectomy. Dr. Aleman is board certified in Ophthalmology, 2019. Dr. Aleman is currently accepting new patients.
Office
Bart Leroy is an Ophthalmologist practicing medicine in Philadelphia, Pennsylvania. Dr. Leroy is rated as an Elite provider by MediFind in the treatment of Leber Congenital Amaurosis. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Leber Congenital Amaurosis, Retinopathy Pigmentary Mental Retardation, Late-Onset Retinal Degeneration, Vitrectomy, and Cataract Removal.
Summary: The purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A\>G (p.Cys998X) mutation in the CEP290.
Summary: The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by the Foundation. It is a patient-initiated registry accessible via a secure on-line portal at www.MyRetinaTracker.org. Affected individuals who register are guided to create a profile that captures their perspective on the...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center
